Growth hormone treatment of osteoporotic postmenopausal women - a one-year placebo-controlled study.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

To study the effect of 12 months of growth hormone (GH) treatment on bone markers, bone mineral density (BMD), lean body mass (LBM) and body fat mass (BF) in postmenopausal osteoporotic women.

Who Took Part

According to the abstract, 14 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

After the first year 14 patients (8 placebo treated, 6 GH treated) were recruited to GH treatment during the second year.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

Bone mineral density and body composition were assessed by dual energy X-ray absorptiometry.

Biochemical bone markers were analysed by RIA or HPLC techniques.

Diurnal GH profiles were performed with continuous venous blood sampling.

What Was Measured

The subject headings attached to it are Absorptiometry, Photon, Biomarkers, Body Composition, Body Height, Bone Density, Growth Hormone and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 14 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 14 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1999 (European journal of endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.